Biological Products, (No Diagnostic Substances) · DE · CIK 1994702
Kyverna Therapeutics develops cell therapies for autoimmune diseases, including its CAR T-cell product candidate KYV-101
Comparable business profile · signals at a glance
In the 90 days to Dec 18, 2025: 2 insiders bought $2.0M · 1 sold $293K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 18, 2025 | Seidenberg Beth CDirector | Buy | 133,333 | $7.50 | $1000K |
| Dec 18, 2025 | Westlake Biopartners Opportunity Fund I, L.P.TenPercentOwner | Buy | 133,333 | $7.50 | $1000K |
| Dec 15, 2025 | Walker Karen MarieChief Technology Officer | Sell | 23,998 | $12.20 | $293K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.